Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU) Reimburse with clinical criteria and/or conditions Complete
Descovy Emtricitabine /tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Humira Adalimumab Hidradenitis suppurativa Reimburse with clinical criteria and/or conditions Complete
Vimizim Elosulfase alfa Mucopolysaccharidosis IVA (Morquio A syndrome) Reimburse with clinical criteria and/or conditions Complete
Xolair Omalizumab (Drug Plan Submission) Asthma, severe persistent Reimburse with clinical criteria and/or conditions Complete
Prolia Denosumab Osteoporosis Reimburse with clinical criteria and/or conditions Complete
Revestive Teduglutide Short bowel syndrome Reimburse with clinical criteria and/or conditions Complete
Gazyva Obinutuzumab Follicular Lymphoma Reimburse with clinical criteria and/or conditions Complete
Blincyto (Resubmission) Blinatumomab Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete